NCT03634267View on ClinicalTrials.gov

MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 3, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Human Papillomavirus-Related CarcinomaHuman Papillomavirus-Related Cervical CarcinomaStage IB2 Cervical Cancer AJCC v8Stage II Cervical Cancer AJCC v8Stage II Vaginal Cancer AJCC v8Stage IIA Cervical Cancer AJCC v8Stage IIA Vaginal Cancer AJCC v8Stage IIA1 Cervical Cancer AJCC v8Stage IIA2 Cervical Cancer AJCC v8Stage IIB Cervical Cancer AJCC v8Stage IIB Vaginal Cancer AJCC v8Stage III Cervical Cancer AJCC v8Stage III Vaginal Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8Stage IVA Vaginal Cancer AJCC v8
Interventions
RADIATION

Internal Radiation Therapy

Undergo brachytherapy

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI scan

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER